Systemic administration of the selective NET inhibitor desipramine increases extracellular DA derived from L-DOPA in 6-hydroxydopamine (6-OHDA)-lesioned rats, indicating that NET could play a significant role in DA clearance in the PD-like striatum and, consequently, may be involved in L-DOPA-derived DA synthesis in PD pathogenesis [29]. Here, SLC6A2 is linked to Parkinson disease.